Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
seasonal split influenza vaccine
- Development stage
- Approved
- Lead developer
- Sinovac Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intradermal
01
Overview
A seasonal split influenza vaccine is a type of inactivated influenza vaccine produced by disrupting (splitting) the influenza virus particles with detergents or solvents. This process reduces the reactogenicity of the vaccine compared to whole-virus vaccines while maintaining immunogenicity by presenting the surface antigens, primarily hemagglutinin (HA) and neuraminidase (NA). These vaccines are typically trivalent or quadrivalent, containing strains of Influenza A (H1N1 and H3N2) and Influenza B (Victoria and/or Yamagata lineages) as recommended annually by the World Health Organization (WHO). They are widely used for the prevention of seasonal influenza in various age groups and are updated each year to match circulating viral strains.
- Brand names
- AnfluFluarixFluzoneVaxigripAfluriaFluLaval
- Other names
- split-virion influenza vaccineinactivated split influenza vaccineHA split vaccinesplit influenza vaccine
02
Targets
HA (Hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on seasonal split influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on seasonal split influenza vaccine.